Selective expression of the target antigen on tumors relative to normal tissues provides the basis for ADC targeting to tumors and minimizes the potential for targeted toxicity in normal tissues. The abundance of the target antigen on the cell surface and its distribution in the tumor (homogeneous vs heterogeneous expression) can be important determinants of ADC efficacy. BOC Sciences provides a comprehensive set of ADC development services for targeted drug discovery, our professional scientists have extensive experience in antibody modification, small molecule synthetic chemistry, and bio-conjugation and are committed to providing high-quality services to promote the development of innovative cancer treatments. We have a dedicated custom development platform that is very convenient for our customers to customize different ADC products and services.
Many potential targets are highly expressed in tumor tissues but also present at low levels in normal tissues, increasing the risk of off-target toxicity. BOC Sciences employs tissue microarrays, high-throughput omics screening, and bioinformatics comparison to accurately identify tumor-specific targets, significantly enhancing safety.
Although a target may be expressed on the surface of tumor cells, insufficient mediation of antibody internalization can impair ADC efficacy. BOC Sciences performs cellular endocytosis assays and colocalization imaging to identify targets with strong internalization activity, ensuring effective drug release.
The same type of tumor may show significant variation in target expression among different patients or subtypes, limiting the applicability of ADCs. We integrate multi-omics databases such as TCGA and clinical sample analysis to identify broadly expressed and adaptive targets, improving development success rates.
Some targets, though highly expressed in tumors, may also be expressed at low levels in specific normal tissues, potentially causing side effects. BOC Sciences conducts cross-tissue target expression analysis and toxicological risk assessment to help clients identify candidate targets with favorable therapeutic indices.
We specialize in precise screening of diverse ADC targets, covering a broad spectrum of clinical and research hotspots including breast cancer, lung cancer, lymphoma, and prostate cancer. Leveraging cutting-edge genomics, proteomics, and immunology technologies, we help clients identify and validate high-potential ADC targets, driving innovation in drug development. With a flexible and efficient screening platform, BOC Sciences offers tailored antibody generation and optimization services for various targets, supporting full-process solutions from target confirmation to drug development.
AXL is a receptor tyrosine kinase involved in tumor cell migration and metastasis, commonly found in NSCLC and TNBC. We offer AXL expression analysis and antibody screening, supporting development and functional validation of high-affinity antibodies.
BCMA is primarily expressed on multiple myeloma cells and is a key ADC target for its treatment. BOC Sciences' multidimensional screening platform rapidly identifies highly specific BCMA antibodies for targeted therapy.
CD19 is a B-cell-specific antigen widely used in targeted therapy for B-cell non-Hodgkin lymphoma and ALL. We provide CD19 protein expression analysis and antibody development support.
CD22 is mainly expressed on B-cell lymphoma cells and is suitable for non-Hodgkin lymphoma and leukemia therapy. BOC Sciences offers functional validation and affinity optimization for CD22 targets.
CD30 is a hallmark target for Hodgkin lymphoma and some T-cell lymphomas. We provide high-throughput screening and customized antibody development for CD30-targeted ADCs.
CD33 is mainly present on AML cells. BOC Sciences provides CD33 target expression detection and antibody development services for AML-targeted ADC projects.
CD79b is a component of the B-cell receptor complex, applicable to B-cell lymphoma treatment. We support antibody screening and conjugation optimization for CD79b-targeted ADC development.
c-MET is a receptor tyrosine kinase associated with tumor growth and metastasis, commonly found in gastric, liver, and NSCLC cancers. BOC Sciences offers multi-technology screening and antibody evaluation for c-MET targets.
EGFR is expressed in many solid tumors, such as NSCLC, colorectal, and head and neck cancers. We provide protein expression analysis and affinity screening for EGFR-targeted ADC design.
FOLR1 (Folate Receptor 1) is overexpressed in ovarian and lung adenocarcinoma. BOC Sciences offers customized antibody screening and validation services for FOLR1 to support targeted therapy development.
HER2 is a classical target in breast and gastric cancers. We offer high-throughput HER2 screening and affinity optimization for efficient ADC antibody development.
Nectin-4 is an emerging target in bladder and other solid tumors. BOC Sciences integrates proteomic and immunological technologies to provide antibody screening and functional validation for Nectin-4.
ROR1, an embryonic development-related receptor, is abnormally expressed in CLL and some lung cancers. We support ROR1 target expression analysis and antibody screening.
Tissue Factor (TF) plays a critical role in tumor angiogenesis and invasion, associated with multiple solid tumors such as liver and pancreatic cancer. BOC Sciences offers TF target screening, antibody development, and in vitro/in vivo functional evaluation.
TROP-2 is a transmembrane protein in various epithelial tumors like breast, lung, and ovarian cancers. Using multi-platform screening technologies, we support efficient TROP-2 antibody selection and conjugation to drive ADC innovation.
BOC Sciences has established a comprehensive ADC development platform focused on full-process support from target identification and antibody screening to conjugation technology. Our platform integrates advanced antibody screening techniques, innovative linker design, efficient cytotoxin synthesis, and precise conjugation processes to ensure every step is optimized around target characteristics, enhancing ADC targeting and therapeutic efficacy. Combined with cGMP-compliant manufacturing capabilities and comprehensive analytical characterization systems, BOC Sciences provides clients with a one-stop, target-oriented ADC development service, facilitating high-quality and efficient ADC drug discovery.
We offer a complete range of services from immunized animals, phage display, to humanized antibody screening. Antibody affinity, specificity, and internalization are evaluated based on target properties, and antibody modification sites are further optimized to achieve high conjugation efficiency and structural uniformity. Multiple conjugation strategies are supported, including amine, thiol, and enzymatic methods.
Serving as the bridge of an ADC, the linker determines drug release mechanisms and stability. BOC Sciences custom-designs chemically cleavable linkers (e.g., hydrazone, disulfide) and enzymatically cleavable linkers (e.g., peptide, glucoside) to achieve precise release under specific conditions. Blood stability and intracellular cleavage efficiency are also evaluated.
We synthesize a variety of commonly used cytotoxic drugs (such as MMAE, DM1, SN-38, PBD) and customize structural modifications according to project requirements to improve solubility, toxicity, targeting, and binding efficiency. Ensuring compatibility with linkers and antibodies is a key step toward efficient ADC construction.
BOC Sciences possesses mature capabilities in linker-payload conjugate design and process scale-up. We optimize reaction pathways and purification procedures to obtain high-purity, well-defined linker-payload constructs that can be directly used for ADC assembly, ensuring process efficiency and product quality.
Our platform supports ADC preparation from laboratory scale to GMP production, covering milligram to hundred-gram scales. The facilities comply with cGMP standards, equipped with isolation systems, sterile filling equipment, and high-potency drug handling capabilities, suitable for both preclinical and clinical stage ADC bulk production.
BOC Sciences is equipped with advanced analytical instruments such as LC-MS, HPLC, CE, UV, and ELISA, establishing a comprehensive ADC analytical method system. We provide precise characterization of critical quality attributes including DAR, residual toxins, polymer content, conjugation sites, purity, and stability.
With extensive experience and technical expertise, we support a wide range of classical and emerging targets including HER2, CD19, and BCMA, covering multiple cancer types such as breast cancer, lymphoma, and myeloma.
Equipped with genomic sequencing, proteomics, and high-throughput cell screening equipment, we enable precise target discovery and rapid functional validation, ensuring screening efficiency and data quality.
With access to humanized antibody libraries, phage display, and hybridoma platforms, we support antibody affinity optimization, immunogenicity reduction, and stability enhancement to meet various ADC conjugation requirements.
Featuring advanced bioconjugation and analytical laboratories, we provide diverse linker design and process optimization services to ensure high stability and controlled DAR of ADC products.
With capabilities in cellular functional analysis, animal models, and pharmacokinetic detection, we comprehensively assess the targeting ability, safety, and efficacy of ADCs to accelerate preclinical development.
We offer end-to-end services from target screening, antibody development, linker design to preclinical research, supported by efficient project management and interdisciplinary teams to drive ADC project success.
Using genomics and proteomics technologies, we screen for potential ADC targets, perform expression analysis and functional validation, confirming target specificity and disease relevance.
Leveraging phage display, humanized antibody libraries, and hybridoma technologies, we rapidly screen high-affinity and highly specific antibodies, followed by affinity enhancement, immunogenicity reduction, and stability optimization.
Based on target and payload characteristics, we design and screen suitable linkers, efficiently conjugate antibodies and cytotoxins, ensuring ADC stability and optimal DRA.
Conduct binding affinity assays, cellular uptake studies, and cytotoxicity tests to assess the targeting and cytotoxic effects of ADCs.
Using animal models, we validate the antitumor activity, pharmacokinetics, and toxicity of ADCs, ensuring the effectiveness and safety of candidate drugs.
We refine the manufacturing process and establish strict quality control standards to ensure batch consistency and product stability, laying a solid foundation for preclinical studies and subsequent clinical development.
Antibody-drug conjugates (ADCs) typically target cell surface proteins that are highly expressed on cancerous cells but show low or no expression on normal tissues. These proteins serve as molecular "addresses" that guide the ADC to tumor cells for selective drug delivery. Common ADC target proteins include:
Yes, several ADCs have received FDA approval, including sacituzumab govitecan, used for treating triple-negative breast cancer (TNBC), demonstrating clinical success and regulatory recognition.
The FDA assesses the expression, specificity, and safety of ADC targets through rigorous clinical trials before approving new ADC therapies for cancer treatment.
An ideal target like TROP-2 is highly expressed on TNBC cells but not on normal tissues, allowing ADCs such as sacituzumab govitecan to deliver cytotoxic payloads effectively to tumor sites.
Accurate target selection ensures high specificity for tumor cells, improves treatment efficacy, and reduces toxicity, making the ADC a precise and effective treatment option.
The services cover a wide range of solid tumors and hematologic malignancies, including breast cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, and more, broadly meeting clinical development needs.
We support the screening and development of various classic and emerging ADC targets such as HER2, CD19, BCMA, TROP-2, etc., covering a wide range of cancer types to meet diverse customer requirements.
We offer one-stop, full-process services including conjugation process design, in vitro and in vivo functional evaluation, and preclinical studies to help clients accelerate ADC drug development.
